The following is a summary of “Pneumatic retinopexy for primary rhegmatogenous retinal detachment: from a clinical trial to the real-life experience,” published in the July 2024 issue of Ophthalmology by Iannetta et al.
Researchers conducted a retrospective study evaluating real-world outcomes in patients of primary rhegmatogenous retinal detachment (RRD) treated with pneumatic retinopexy (PnR) based on PIVOT trial indications.
They included patients who underwent PnR for RRD (2021 to 2023), with a minimum follow-up of 6 months. The documentation of single-procedure anatomical success, final anatomical success, complications, causes of failures, best corrected visual acuity (BCVA) after surgery, and vision-related QoL as measured by the 25-Item National Eye Institute Visual Function Questionnaire (NEI VFQ-25) was done.
The result showed 76 eyes from 76 patients, with a mean age of 60 ± 8.1 years. Primary anatomical reattachment was achieved in 84.3% of patients, while 100% reached final anatomical reattachment following pars plana vitrectomy. A significant improvement was observed in BCVA, increasing from 0.32 (20/40) to 0.04 (20/20) logMar (P<0.001) at the 6-month mark. The main reason for failure was attributed to additional (potentially missed) retinal breaks, comprising 66.6% of cases. Additionally, older age, macular involvement, poorer baseline BCVA, larger extent of RRD, and longer time from diagnosis to treatment were associated with a higher frequency of primary PnR failure. The average composite score on the NEI-VFQ 25 at 6 months was 93.9% ± 6.4.
Investigators concluded that the PIVOT trial criteria effectively guided real-world decisions for primary RRD treatment, achieving positive anatomical and functional results.
Source: bmcophthalmol.biomedcentral.com/articles/10.1186/s12886-024-03559-7
